Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 5:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 221 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Rosuvastatin calcium Clear all

Conditions: Healty Volunteers
Interventions: KP-001, Rosuvastatin calcium10mg, Caffeine citrate, Fluvoxamine; Drug
Lead sponsor: Kaken Pharmaceutical; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy
Interventions: Rosuvastatin, Rosuvastatin plus rifampin; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Postbariatric Hypoglycemia
Interventions: MBX 1416 (Part A), MBX 1416 (Part B), Placebo, MBX 1416 (Part C); Drug
Lead sponsor: MBX Biosciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Rheumatoid Arthritis
Interventions: Fostamatinib, Rosuvastatin, Simvastatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy Volunteer
Interventions: NX-5948, Esomeprazole, Placebo, Famotidine, Midazolam, Digoxin, Rosuvastatin, Quinidine; Drug
Lead sponsor: Nurix Therapeutics, Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 223 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Phoenix, Arizona • Lincoln, Nebraska

Conditions: Hypercholesterolemia
Interventions: Rosuvastatin, Ezetimibe; Drug
Lead sponsor: Bronx VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Advanced Solid Tumors, Metastatic Melanoma
Interventions: losartan, dextromethorphan, caffeine, omeprazole, midazolam, rosuvastatin, bupropion immediate release (IR), encorafenib, binimetinib, modafinil; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 11
States / cities: Orange, California • Aurora, Colorado • Chicago, Illinois + 7 more

Conditions: Carotid Artery Stenosis, Strokes
Interventions: Statin, Atorvastatin, Placebo; Drug · Other
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 7
States / cities: Ridgewood, New Jersey • Albany, New York • Buffalo, New York + 1 more

Conditions: Dyslipidemia
Interventions: Rosuvastatin, Atorvastatin; Drug
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 8 Years to 21 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Sepsis, Acute Lung Injury
Interventions: Rosuvastatin, Placebo; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older
Enrollment: 745 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 40
States / cities: Fresno, California • Sacramento, California • San Francisco, California + 20 more

Conditions: Dyslipidemia, Renal Insufficiency
Interventions: ABT-335, Rosuvastatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 6
States / cities: Gainesville, Florida • Miami, Florida • Minneapolis, Minnesota + 3 more

Conditions: Acute Respiratory Distress Syndrome, Influenza, H1N1 Influenza
Interventions: Rosuvastatin (crestor), Placebo; Drug
Lead sponsor: Gordon Bernard; Other
Eligibility: 13 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 21
States / cities: Little Rock, Alaska • Phoenix, Arizona • Stanford, California + 17 more

Conditions: Diabetes Mellitus
Interventions: Rosuvastatin, Atorvastatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 353 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 29
States / cities: Avondale, Arizona • Phoenix, Arizona • Jonesboro, Arkansas + 26 more

Conditions: Atherosclerosis, Cardiovascular Disease
Interventions: any statin, niacin, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 65 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hypercholesteremia
Interventions: Rosuvastatin calcium; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 45 Years to 70 Years
Enrollment: 840 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 20
States / cities: Alhambra, California • La Jolla, California • Los Angeles, California + 17 more

Conditions: Healthy Adult Participants
Interventions: BGB-43395, Midazolam, Celecoxib, Dabigatran etexilate, Rosuvastatin; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy
Interventions: Rosuvastatin, Furosemide, MK-2828; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 24 Years to 60 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Atherosclerosis
Interventions: Statin therapy, Lifestyle modification; Drug · Behavioral
Lead sponsor: Emory University; Other
Eligibility: 22 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Chronic Hepatitis C
Interventions: standard of care, fluvastatin; Drug
Lead sponsor: Bader, Ted, M.D.; Individual
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Hypertriglyceridemia
Interventions: AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo; Drug
Lead sponsor: Amarin Pharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 18
States / cities: Sacramento, California • Golden, Colorado • Miami, Florida + 13 more

Conditions: Healthy Participants
Interventions: DC-806, Midazolam, Repaglinide, Digoxin, Rosuvastatin; Drug
Lead sponsor: DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Lipid Disorder, Hypercholesterolemia, Cardiovascular Diseases, Atherosclerosis
Interventions: Statin (rosuvastatin 10 or 40 mg daily, depending on risk), Healthy Lifestyle Counseling, Outpatient Followup; Drug · Behavioral · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 40 Years to 75 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: RSV Infection, Drug Drug Interaction
Interventions: EDP-323, Midazolam, Caffeine, Rosuvastatin; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Breast Cancer
Interventions: rosuvastatin; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Boston, Massachusetts

Search by objective public record fields.

To Determine the Effect of KP-001 on Rosuvastatin, Caffeine PK and the Effect of Fluvoxamine on KP-001 PK in Volunteers

The Effects of Rifampin on the Pharmacokinetics of Rosuvastatin

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of MBX 1416 in Healthy Subjects

Assess the Pharmacokinetics of Rosuvastatin and Simvastatin When Administered Alone or in Combination With Fostamatinib

A Single and Multiple Ascending Doses, Relative Bioavailability, Food Effect, and Drug-Drug Interaction Study of NX-5948 in Healthy Volunteers

Tolerability and Lipid Lowering Effect of Weekly/Biweekly Crestor in Statin Intolerant Patients Treated With Zetia

Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

Statin Neuroprotection and Carotid Endarterectomy: Safety, Feasibility and Outcomes

Pharmacokinetics of Rosuvastatin and Atorvastatin in Pediatric Dyslipidemia Patients

Statins for Acutely Injured Lungs From Sepsis

Safety Study to Evaluate the Effects of Mild and Moderate Renal Impairment on the Pharmacokinetics of ABT-335 and Rosuvastatin When Administered Concomitantly

STIP: Statin Trial for Influenza Patients

Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease

High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly

A Study Measuring Effects on Intima Media Thickness: An Evaluation of Rosuvastatin 40 mg (METEOR)

A Trial in Healthy Participants to Assess Drug Interaction Potential of BGB-43395

A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005)

Accelerated Atherosclerosis in High Risk Population Groups: An Assessment by Magnetic Resonance Imaging

Fluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin

Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL

A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy Participants

Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial

A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants

Rosuvastatin to Lower Circulating Tissue Factor Bearing Microparticles in Metastatic Breast Cancer